**Supplementary Table 1. Characteristics of included studies.**

| **Etude N°** | **Author et al.** | **Year of publication** | **Country where the study was undertaken** | **Original (Y:yes/N:no)** | **Comparative (Y:yes/N:no)** | **Randomized (Y:yes/N:no)** | **Brand name of TAVI** | **Access type of TAVI** | **Number of patients** | **Funding** | **Level of evidence** | **Center** | **Single-center public or private** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | Leclercq F et al. | 2017 | France | Y | Y | Y | Edwards™ Sapien® | Transfemoral | 240 | Private | I | Single-center | Public |
| 2 | Deeb G et al. | 2017 | USA | N | N | N | Medtronic™ CoreValve® | Transfemoral, Transaxillary, Transaortic | 227 | Private | III | Multicenter |  |
| 3 | Musa TA et al. | 2017 | UK | N | Y | N | Medtronic™ CoreValve® /Boston Scientific™ Lotus™ Aortic Valve | Transfemoral | 98 | Public | II | Single-center | Public |
| 4 | Greenbaum AB et al. | 2017 | USA | Y | N | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral | 100 | Public | III | Multicenter |  |
| 5 | Attizzani GF et al. | 2017 | Italy | N | Y | N | Medtronic™ CoreValve® | Transfemoral, Transapical, Subclavian | 2069 | NS | II | Multicenter |  |
| 6 | Sinning JM et al. | 2017 | Germany | Y | Y | N | Medtronic™ CoreValve® | NS | 173 | Private | II | Multicenter |  |
| 7 | D'Ancona G et al. | 2017 | Germany | Y | Y | N | DFM™ Direct Flow Medical™ | Transfemoral | 118 | NS | II | Multicenter |  |
| 8 | Conte L et al. | 2017 | Italy | N | N | N | Medtronic™ CoreValve® | NS | 166 | NS | III | Single-center | Public |
| 9 | Eidet J et al. | 2016 | Norway | N | Y | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral, Transaortic, Transapical | 64 | Public | II | Single-center | Public |
| 10 | Ahn HC et al. | 2016 | Sweden | Y | Y | Y | Edwards™ Sapien® | Transfemoral, Transapical | 60 | NS | I | Single-center | Public |
| 11 | Deeb GM et al. | 2016 | USA | N | Y | Y | Medtronic™ CoreValve® | Transfemoral | 750 | Private | I | Multicenter |  |
| 12 | Thyregod HGH et al. | 2016 | Denmark | Y | Y | N | Medtronic™ CoreValve® | Transfemoral, Transaxillary | 487 | Fondation | II | Single-center | Public |
| 13 | Barbanti M et al. | 2016 | Italy | Y | Y | N | Medtronic™ CoreValve® /Edwards™ Sapien® | NS | 377 | NS | II | Single-center | Public |
| 14 | Ribera A et al. | 2015 | Spain | Y | Y | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral | 231 | Public | II | Multicenter |  |
| 15 | Muneretto C et al. | 2015 | Italy | Y | Y | N | Medtronic™ CoreValve® | Transfemoral | 163 | NS | II | Multicenter |  |
| 16 | Pascual I et al. | 2015 | Spain | N | N | N | Medtronic™ CoreValve® | Transfemoral, Transapical, Transaxillary | 160 | NS | III | Multicenter |  |
| 17 | Popma JJ et al. | 2014 | USA | Y | N | N | Medtronic™ CoreValve® | Transfemoral | 506 | Private | III | Multicenter |  |
| 18 | Fanning JPet al. | 2014 | Australia | Y | Y | N | Edwards™ Sapien® | Transfemoral, Transapical, Transaortic | 80 | NS | II | Multicenter |  |
| 19 | Schofer J et al. | 2014 | Germany | Y | N | N | DFM™ Direct Flow Medical™ | Transfemoral | 100 | NS | III | Multicenter |  |
| 20 | Webb J et al. | 2014 | Canada | Y | Y | N | Edwards™ Sapien® | Transfemoral, Transapical, Transaortic | 150 | Private | II | Multicenter |  |
| 21 | Wendt D et al. | 2014 | Germany | Y | N | N | Boston Scientific™ Accurate™ | Transapical | 8 | Public | III | Single-center | Public |
| 22 | Barbanti M et al. | 2014 | Italy | N | Y | N | Medtronic™ CoreValve® | Transfemoral, Subclavian, Transaortic | 1376 | Private | II | Multicenter |  |
| 23 | Kasel AM et al. | 2014 | Germany | N | Y | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral, Transapical | 185 | Private | II | Single-center | Private |
| 24 | Sawa Y et al. | 2014 | Japan | Y | Y | N | MDT-2111 TAV | Transfemoral, Subclavian, Transaortic | 55 | Private | II | Multicenter |  |
| 25 | Hong SJ et al. | 2014 | Korea | N | Y | N | Medtronic™ CoreValve® | Transfemoral, Subclavian, Transaortic | 59 | NS | II | Single-center | Public |
| 26 | Fiorina C et al. | 2014 | Italy | N | Y | N | Medtronic™ CoreValve® | Transfemoral, Subclavian, Transaortic | 100 | NS | II | Single-center | Public |
| 27 | Reinöhl J et al. | 2013 | Germany | N | N | N | Medtronic™ CoreValve® | Transfemoral | 60 | NS | III | Single-center | Public |
| 28 | Gotzmann M et al. | 2013 | Germany | Y | N | N | Medtronic™ CoreValve® | Transfemoral, Subclavian | 202 | NS | III | Single-center | Public |
| 29 | Kempfert J et al. | 2013 | Germany | N | N | N | Edwards™ Sapien® | Transapical | 40 | Private | III | Multicenter |  |
| 30 | Treede H et al. | 2012 | Germany | Y | N | N | Jenavalve GmbH™ JenaValve™ | Transapical | 67 | Private | III | Multicenter |  |
| 31 | Osnabrugge RLJ et al. | 2012 | Netherland | Y | Y | N | Medtronic™ CoreValve® | Transfemoral | 546 | NS | II | Single-center | Public |
| 32 | Jegaden O et al. | 2012 | France | Y | Y | N | Edwards™ Sapien® | Transfemoral, Transapical | 23 | NS | II | Single-center | Public |
| 33 | Yamamoto M et al. | 2012 | France | N | Y | N | Medtronic™ CoreValve® | Transfemoral, Subclavian, Carotid | 136 | NS | II | Single-center | Public |
| 34 | Walther T et al. | 2012 | Germany | N | N | N | Edwards™ Sapien® | Transapical | 150 | Private | III | Multicenter |  |
| 35 | Takagi K et al. | 2011 | Italy | Y | N | N | Medtronic™ CoreValve® | Transfemoral, Transaxillary | 79 | NS | III | Single-center | Public |
| 36 | Walther T et al. | 2011 | Germany | N | N | N | Cribier/Edwards™ Sapien® | Transapical | 168 | NS | III | Multicenter |  |
| 37 | Modine T et al. | 2011 | France | Y | N | N | Medtronic™ CoreValve® | Subclavian, Transaxillary | 17 | NS | III | Multicenter |  |
| 38 | John D et al. | 2010 | Germany | N | N | N | Medtronic™ CoreValve® | Transfemoral | 100 | Devices provided by private funding | III | Single-center | Private |
| 39 | Krane M et al. | 2010 | Germany | Y | Y | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral, Transapical | 99 | Public | II | Single-center | Public |
| 40 | Clavel MA et al. | 2009 | Canada | Y | Y | N | Cribier/Edwards™ Sapien® | Transfemoral, Transapical | 150 | Public + Private | II | Multicenter |  |
| 41 | Grube E et al. | 2008 | Germany | Y | Y | N | Medtronic™ CoreValve® | Transfemoral, Subclavian | 136 | Public + Private | II | Single-center | Private |
| 42 | Wöhrle J et al. | 2016 | Italy | Y | Y | N | Edwards™ Sapien® | Transfemoral | 235 | NS | II | Single-center | Public |
| 43 | Gooley RP et al. | 2015 | Australia | Y | Y | N | Medtronic™ CoreValve® | Transfemoral | 100 | NS | II | Single-center | Private |
| 44 | Kapadia S et al. | 2015 | USA | N | Y | Y | Edwards™ Sapien® | Transfemoral | 179 | Private | I | Multicenter |  |
| 45 | Reardon MJ et al. | 2014 | USA | Y | N | N | Medtronic™ CoreValve® | Transfemoral, Subclavian, Transaortic | 150 | Private | III | Multicenter |  |
| 46 | Spethmann S et al. | 2014 | Germany | Y | Y | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral, Transapical | 99 | NS | II | Single-center | Public |
| 47 | Yamamoto M et al. | 2013 | France | Y | Y | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral, Subclavian, Transcarotid | 75 | NS | II | Single-center | Public |
| 48 | Wendler O et al. | 2012 | UK | Y | N | N | Edwards™ Sapien® | Transapical | 6 | NS | III | Single-center | Public |
| 49 | Yared K et al. | 2012 | USA | Y | N | N | Edwards™ Sapien® | Transfemoral, Transapical | 95 | NS | III | Multicenter |  |
| 50 | Nielsen HM et al. | 2012 | Denmark | Y | Y | Y | Edwards™ Sapien® | Transapical | 525 | Public | I | Multicenter |  |
| 51 | Kempfert J et al. | 2012 | Germany | N | N | N | Boston Scientific™ Accurate™ | Transapical | 51 | Private | III | Single-center | Private |
| 52 | Modine T et al. | 2012 | France | Y | N | N | Medtronic™ CoreValve® | Transapical | 12 | NS | III | Multicenter |  |
| 53 | Ong SH et al. | 2012 | Germany | N | N | N | Medtronic™ CoreValve® | Transfemoral | 18 | Private | III | Multicenter |  |
| 54 | Modine T et al. | 2012 | France | Y | N | N | Medtronic™ CoreValve® | Subclavian, Transaxillary | 19 | NS | III | Multicenter |  |
| 55 | Grube E et al. | 2011 | Germany | Y | N | N | Medtronic™ CoreValve® | NS | 60 | NS | III | Multicenter |  |
| 56 | Lefèvre T et al. | 2011 | France | Y | Y | N | Edwards™ Sapien® | Transfemoral, Transapical | 130 | Private | II | Multicenter |  |
| 57 | Bruschi G et al. | 2012 | Italy | N | N | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral, Transaxillary, Transapical | 141 | NS | III | Single-center | Public |
| 58 | Eidet J et al. | 2015 | Norway | Y | N | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral, Transapical, Transaortic | 40 | Public | III | Single-center | Public |
| 59 | Adams DH et al. | 2014 | USA | Y | Y | Y | Medtronic™ CoreValve® | Transfemoral | 795 | Private | I | Multicenter |  |
| 60 | Grube E et al. | 2007 | Germany | Y | Y | N | Medtronic™ CoreValve® | Transfemoral, Subclavian | 86 | NS | II | Multicenter |  |
| 61 | Hernández-Antolín RA et al. | 2011 | Spain | Y | Y | N | Medtronic™ CoreValve® /Edwards™ Sapien® | Transfemoral | 76 | NS | II | Single-center | Public |
| 62 | Fraccaro C et al. | 2009 | Italy | Y | N | N | Medtronic™ CoreValve® | Subclavian | 3 | NS | III | Single-center | Public |
| 63 | Webb JG et al. | 2006 | Canada | Y | N | N | Cribier | Transfemoral | 18 | NS | III | Single-center | Public |
| 64 | Gurvitch R et al. | 2011 | Canada | Y | Y | N | Edwards™ Sapien® | Transfemoral, Transapical | 270 | NS | II | Single-center | Public |
| 65 | Kempfert J et al. | 2011 | Germany | Y | Y | N | Edwards™ Sapien® | Transfemoral, Transapical | 299 | NS | II | Single-center | Public |
| 66 | Webb J et al. | 2007 | Canada | Y | Y | N | Edwards™ Sapien® | Transfemoral | 50 | NS | II | Single-center | Public |
| 67 | Leon MB et al. | 2010 | USA | Y | Y | Y | Edwards™ Sapien® | Transfemoral | 358 | Private | I | Multicenter |  |
| 68 | Kempfert J et al. | 2011 | Germany | Y | N | N | Boston Scientific™ Accurate™ | Transapical | 40 | NS | III | Multicenter |  |

*NS: not stated ; Level I: High quality randomized trial or prospective study; testing of previously developed diagnostic criteria on consecutive patients; sensible costs and alternatives; values obtained from many studies with multiway sensitivity analyses; systematic review of Level I RCTs and Level I studies; Level II: Lesser quality RCT; prospective comparative study; retrospective study; untreated controls from an RCT; lesser quality prospective study; development of diagnostic criteria on consecutive patients; sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses; systematic review of Level II studies or Level I studies with inconsistent result;. Level III: Case control study (therapeutic and prognostic studies); retrospective comparative study; study of nonconsecutive patients without consistently applied reference “gold” standard; analyses based on limited alternatives and costs and poor estimates; systematic review of Level III studies; Level IV: Case series; case control study (diagnostic studies); poor reference standard; analyses with no sensitivity analyses; Level V: Expert opinion.*